83 related articles for article (PubMed ID: 8832755)
1. Cytokeratin profiles and mucin secretion in combined hepatocellular-cholangiocarcinoma. A case report.
Hauben E; Struyf N; Michielsen P; van Marck E
Pathol Res Pract; 1996 May; 192(5):488-91. PubMed ID: 8832755
[TBL] [Abstract][Full Text] [Related]
2. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
3. A mixed hepatocellular carcinoma and cholangiocarcinoma: dual expression of biliary-type cytokeratin and hepatocyte specific marker.
Tanaka S; Hirohashi K; Uenishi T; Yamamoto T; Hamba H; Kubo S; Tanaka H; Shuto T; Ogawa M; Kinoshita H
Hepatogastroenterology; 2004; 51(57):839-41. PubMed ID: 15143930
[TBL] [Abstract][Full Text] [Related]
4. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
5. Cytomorphology of combined hepatocellular-cholangiocarcinoma in fine needle aspirates of the liver. A report of two cases.
Kilpatrick SE; Geisinger KR; Loggie BW; Hopkins MB
Acta Cytol; 1993; 37(6):943-7. PubMed ID: 7504382
[TBL] [Abstract][Full Text] [Related]
6. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Leong AS; Sormunen RT; Tsui WM; Liew CT
Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
[TBL] [Abstract][Full Text] [Related]
7. Expression of mucin core protein of mammary type in primary liver cancer.
Sasaki M; Nakanuma Y
Hepatology; 1994 Nov; 20(5):1192-7. PubMed ID: 7523272
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic features and diagnosis of mixed type hepatocellular carcinoma].
Lu J; Lin Z; Yuan S
Zhonghua Zhong Liu Za Zhi; 1995 May; 17(3):208-11. PubMed ID: 7656828
[TBL] [Abstract][Full Text] [Related]
9. [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Hayashi H; Beppu T; Ishiko T; Mizumoto T; Masuda T; Okabe K; Baba Y; Okabe H; Takamori H; Kanemitsu K; Hiroto M; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1941-3. PubMed ID: 17212153
[TBL] [Abstract][Full Text] [Related]
10. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
11. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
13. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
14. A clinicopathological study on combined hepatocellular and cholangiocarcinoma.
Taguchi J; Nakashima O; Tanaka M; Hisaka T; Takazawa T; Kojiro M
J Gastroenterol Hepatol; 1996 Aug; 11(8):758-64. PubMed ID: 8872774
[TBL] [Abstract][Full Text] [Related]
15. Genetic classification of combined hepatocellular-cholangiocarcinoma.
Fujii H; Zhu XG; Matsumoto T; Inagaki M; Tokusashi Y; Miyokawa N; Fukusato T; Uekusa T; Takagaki T; Kadowaki N; Shirai T
Hum Pathol; 2000 Sep; 31(9):1011-7. PubMed ID: 11014564
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma.
Haratake J; Hashimoto H
Liver; 1995 Feb; 15(1):9-15. PubMed ID: 7539881
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan.
Ozyilkan E; Ozyilkan O; Firat D; Telatar H
Cancer; 1994 Apr; 73(7):2002-3. PubMed ID: 8137230
[No Abstract] [Full Text] [Related]
19. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study.
Tickoo SK; Zee SY; Obiekwe S; Xiao H; Koea J; Robiou C; Blumgart LH; Jarnagin W; Ladanyi M; Klimstra DS
Am J Surg Pathol; 2002 Aug; 26(8):989-97. PubMed ID: 12170085
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
